Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off

Maria Farris (), Stephen Goodall, Richard Abreu Lourenco, Brendan Mulhern, Kathleen Manipis, Elena Meshcheriakova and Milena Lewandowska
Additional contact information
Maria Farris: Novartis Pharmaceuticals Australia
Stephen Goodall: University of Technology Sydney
Richard Abreu Lourenco: University of Technology Sydney
Brendan Mulhern: University of Technology Sydney
Kathleen Manipis: University of Technology Sydney
Elena Meshcheriakova: University of Technology Sydney
Milena Lewandowska: University of Technology Sydney

PharmacoEconomics - Open, 2024, vol. 8, issue 6, No 11, 922 pages

Abstract: Abstract Purpose Inherited retinal disease (IRD) causes progressive loss of visual function, degenerating towards complete blindness. Economic evaluation of gene therapies for rare forms of genetic IRDs have had to rely on health-related quality of life (HR-QoL) estimates from other diseases because there is limited data available for such a rare condition. This study aimed to estimate Australian societal-based utility values for IRD health states that can be used in cost-utility analyses (CUA) using a time trade-off (TTO) protocol adapted from a UK study. Methods The EuroQol Valuation Technology (EQVT) protocol composite TTO (cTTO) framework was followed, which includes worse-than-death (WTD) states and quality control (QC) measures. Preferences were collected from a general population sample of 110 Australian adult participants. Five health state vignettes from the UK study which had been validated with patients and clinicians were presented randomly to participants during videoconferencing (VC) interviews with one of four interviewers. Technical and protocol feasibility were assessed in a pilot of 10 interviews. QC measures were used to monitor interviewers’ performance during the study. Results One participant withdrew consent. The final analysis was conducted on 109 respondents (including 4 non-traders). The average time to complete the interview was 44.2 minutes (SD 8.7). Participants reported mean visual analogue scale (VAS) scores between 63.15 for ‘moderate impairment’ and 17.98 for ‘hand motion’ to ‘no light perception’. Mean health state utilities (HSU) varied between 0.76 (SD 0.26) in ‘moderate impairment’, and 0.20 (SD 0.58) in ‘hand motion’ to ‘no light perception’. Of all HSU evaluations, 14% were considered WTD which most commonly occurred in the most severe visually impaired health state. Conclusion This study provides valuable information on HSUs across a range of IRD health states from the Australian general population perspective. The utilities obtained in this study can be used as inputs into CUA of IRD therapies.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00515-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00515-5

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00515-5

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().